GSK2586881

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Healthy VolunteersHypertension, Pulmonary

Phase 1

Study of GSK2586881 on Acute Hypoxia and Exercise

TerminatedNCT03000686

GlaxoSmithKlineHealthy Volunteers

Start: 2017-05-17End: 2019-01-04Updated: 2019-12-23

Phase 2

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

CompletedNCT03177603

GlaxoSmithKlineHypertension, Pulmonary

Start: 2018-02-21End: 2019-05-07Updated: 2020-04-21

Related Papers

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Pulmonary Circulation2021-12-1714 citations